Biotech Values

[genisi]

Re: CYP-1020 trial sites

Of course, I'd feel better if the majority of sites/patients were in the US but I find Dr. Laster to be reliable (otherwise I wouldn't have touched BiolinRx).
Clinical trials of antipsychotic have high dropout rates (it was over 70% in the 18 months CATIE study). The 47% dropout rate in the US group is within the range for this treatment. Also cognitive improvement was found at all sites and as I said in the earlier post, the positive/negative syndrome scale (PANSS) score and side effects were 'norm' for Risperidonein. The number of patients enrolled to extension as well as sites were indeed limited for financial reasons.